Frankfurt - Delayed Quote EUR

Jaguar Health, Inc. (1JAA.F)

0.1637 +0.0158 (+10.68%)
At close: April 26 at 9:50 PM GMT+2
Key Events
Loading Chart for 1JAA.F
DELL
  • Previous Close 0.1479
  • Open 0.1455
  • Bid 0.1637 x --
  • Ask 0.1749 x --
  • Day's Range 0.1455 - 0.1800
  • 52 Week Range 0.0425 - 0.9720
  • Volume 64,850
  • Avg. Volume 70,039
  • Market Cap (intraday) 48.193M
  • Beta (5Y Monthly) 1.38
  • PE Ratio (TTM) --
  • EPS (TTM) -1.6700
  • Earnings Date May 13, 2024 - May 17, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

jaguar.health

49

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 1JAA.F

Q4 2023 Jaguar Health Inc Earnings Call

Performance Overview: 1JAA.F

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

1JAA.F
19.49%
S&P 500
6.92%

1-Year Return

1JAA.F
67.19%
S&P 500
25.26%

3-Year Return

1JAA.F
99.95%
S&P 500
22.00%

5-Year Return

1JAA.F
99.99%
S&P 500
74.29%

Compare To: 1JAA.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1JAA.F

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    48.19M

  • Enterprise Value

    76.74M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.42

  • Price/Book (mrq)

    10.17

  • Enterprise Value/Revenue

    7.86

  • Enterprise Value/EBITDA

    -2.32

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -43.17%

  • Return on Equity (ttm)

    -2,366.62%

  • Revenue (ttm)

    9.76M

  • Net Income Avi to Common (ttm)

    -41.3M

  • Diluted EPS (ttm)

    -1.6700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.47M

  • Total Debt/Equity (mrq)

    757.48%

  • Levered Free Cash Flow (ttm)

    -17.15M

Company Insights: 1JAA.F